DR-389 Multi-omics pan-cancer profiling
The changes to the DNA (mutations) found in a tumour are expected to be largely unique to each tumour as there are 3 billion places in the DNA that can be changed. However, in a cancer study with 2,583 participants we observed over a million non-unique mutations. We used characteristics of these mutations and all mutations detected, to classify the tumours into 16 groups that have clinical relevance. We want to refine these classes to gain further insights into the biological processes inducing mutations (‘mutagenesis’), inform on treatment, help in diagnosis, and predict the origin of a metastatic tumor.
Ivo Gut, Centro Nacional de Análisis Genómico, Spain
Terug naar nieuwsMeer nieuws
Measuring the effects of radiotherapy on cancer may open up avenues for treatment
Radiotherapy works by damaging the DNA of cancer cells. It’s an effective strategy overall, but many cancers have subsets of …
Nieuwe voorzitter Data Access Board benoemd: Ele Visser
‘De balans houden,’ daar is het Ele Visser, de nieuwe voorzitter van de Data Access Board (DAB) van Hartwig Medical …
Hartwig Medical Foundation verwelkomt nieuwe algemeen directeur
Hartwig Medical Foundation is verheugd om te melden dat Robert Jan Lamers op 1 september is gestart als haar nieuwe algemeen directeur. Hij …
In ons vak is het heel belangrijk om naast de kennis over de patiënt meer kennis te hebben van de tumor van de patiënt.